Laquinimod Catalog No.:M11360-2 (1986) Proc Natl Acad Sci

(1986) Proc Natl Acad Sci USA

Smiles: CC(=O)N1CCN(CC1)C1C=CC(=CC=1)OC[C@H]1CO[C@@](CN2C=NC=C2)(O1)C1=CC=C(Cl)C=C1Cl

InChiKey: VWRCYAZJKNPEQR-NIEARKAZSA-N

InChi: InChI=1S/C25H23F3N4O2/c26-25(27

Smiles: OC(=O)C1CCN(CC1)C1=NC=C(C=C1Cl)C(=O)NC1=NC(=C(S1)N1CCN(CC1)C1CCCCC1)C1=CC(Cl)=CS1

Laquinimod Catalog No.:M11360-2 (1986) Proc Natl Acad SciLaquinimod, also known as, is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS). Laquinimod is the successor of Active Biotech's failed experimental immunomodulator linomide. Laquinimod seems to be able to reduce the MS disease activity on MRI. In 2011, Teva announced its clinical trials involving laquinimod had failed, being unable to significantly reduce